ViroGates AS (OCSE:VIRO) Loans Receivable: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:VIRO ViroGates AS OCSE:VIRO
45 GF Score
Price kr11.40
GF Value kr6.64
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is ViroGates AS Loans Receivable?

ViroGates AS OCSE:VIRO -5.00% 45 Loans Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus rates OCSE:VIRO with a GF Score™ of 45/100 and a GF Value™ of kr6.64 (Significantly Overvalued). The stock has 2 warning signs investors should review.

ViroGates AS's Loans Receivable for the quarter that ended in Mar. 2026 was kr0.00 Mil.

ViroGates AS Loans Receivable Historical Data

* Premium members only.

The historical data trend for ViroGates AS's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS Loans Receivable Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OCSE:VIRO
45GF Score
ViroGates AS OCSE:VIRO
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ViroGates AS Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of kr0.00 Mil mean?
ViroGates AS (OCSE:VIRO) has a Loans Receivable of kr0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on ViroGates AS and its competitors.
Is ViroGates AS's Loans Receivable too high?
ViroGates AS's current Loans Receivable is kr0.00 Mil. Overall, ViroGates AS has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's Loans Receivable compare to ABT and SYK?
ViroGates AS's Loans Receivable of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Medical Devices & Instruments company?
A good Loans Receivable depends on the Medical Devices & Instruments industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on ViroGates AS and its competitors. ViroGates AS's current Loans Receivable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
Based on GuruFocus' analysis, ViroGates AS (OCSE:VIRO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.64, compared to a current price of kr11.40 — trading 71.7% above its estimated fair value. The current Loans Receivable is kr0.00 Mil. ViroGates AS's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For ViroGates AS (OCSE:VIRO), the current Loans Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (OCSE:VIRO) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of kr11.40 is trading 71.7% above its estimated GF Value™ of kr6.64. GuruFocus considers ViroGates AS to be Significantly Overvalued.

Key valuation signals for OCSE:VIRO:

  • Loans Receivable: kr0.00 Mil
  • GF Value™: kr6.64 vs. price of kr11.40 (71.7% above fair value)
  • GF Score™: 45/100 with 2 warning signs

No single metric tells the full story. See the OCSE:VIRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ViroGates AS Business Description

Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
45GF Score

Get the complete analysis for OCSE:VIRO

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr11.40
Price
kr6.64
GF Value